MLTX MoonLake Immunotherapeutics
Pharmaceutical Preparations · Nasdaq · SEC CIK 1821586 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-29.9%
TTM EPS YoY-9.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-81.6%
ROA-57.3%
ROIC (approx.)-384.1%
Asset turnover—
Leverage & solvency
Liabilities / assets29.4%
Debt / equity0.26x
Current ratio9.13x
Interest coverage-28.98x
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $68.87M | $50.22M | $54.52M | $56.01M | $60.63M | $49.76M | $36.46M | $40.36M |
| SG&A expense | $10.98M | $11.44M | $15.51M | $9.21M | $10.80M | $10.94M | $11.03M | $9.22M |
| Operating income | -$79.85M | -$61.66M | -$70.02M | -$65.22M | -$71.43M | -$60.70M | -$47.48M | -$49.58M |
| Interest expense | $2.65M | $2.63M | $2.27M | $1.99M | $3.20M | $2.04M | $18,000 | $0 |
| Income tax | $631,000 | $90,000 | $622,000 | $248,000 | $115,000 | $95,000 | $153,000 | $41,000 |
| Net income | -$79.55M | -$61.80M | -$69.71M | -$62.43M | -$69.73M | -$55.22M | -$39.94M | -$45.60M |
| EBITDA | -$78.95M | -$60.76M | -$69.18M | -$64.47M | -$70.69M | -$59.96M | -$47.11M | -$49.22M |
| EPS (basic) | -0.93 | -0.84 | -0.98 | — | -1.10 | -0.87 | -0.63 | — |
| EPS (diluted) | -0.93 | -0.84 | -0.98 | — | -1.10 | -0.87 | -0.63 | — |
| Weighted avg. shares (diluted) | 85.38M | 73.92M | 71.27M | — | 63.37M | 63.28M | 63.23M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $379.70M | $477.90M | $298.49M | $334.52M | $350.74M | $306.68M | $271.57M | $180.43M |
| Short-term investments | $118.76M | $59.12M | $59.43M | $59.45M | $29.74M | $118.40M | $208.56M | $267.60M |
| Current assets | $533.34M | $570.04M | $396.64M | $421.69M | $411.21M | $455.48M | $506.26M | $474.29M |
| PP&E, net | $443,000 | $487,000 | $532,000 | $577,000 | $622,000 | $667,000 | $711,000 | $722,000 |
| Total assets | $540.72M | $573.95M | $400.37M | $424.43M | $414.33M | $460.10M | $511.26M | $477.93M |
| Current liabilities | $58.43M | $45.39M | $46.11M | $45.48M | $48.37M | $27.36M | $23.98M | $22.46M |
| Long-term debt | $100.01M | $99.51M | $99.02M | $74.10M | $73.74M | $73.38M | $73.02M | $0 |
| Total debt | $100.01M | $99.51M | $99.02M | $74.10M | $73.74M | $73.38M | $73.02M | $0 |
| Total liabilities | $159.09M | $145.75M | $146.35M | $119.95M | $123.14M | $102.15M | $98.68M | $24.54M |
| Shareholders' equity | $381.63M | $428.19M | $254.02M | $304.48M | $288.91M | $353.73M | $407.52M | $446.82M |
| Net debt | -$279.69M | -$378.39M | -$199.47M | -$260.42M | -$277.00M | -$233.30M | -$198.54M | -$180.43M |
| Cash flow statement | ||||||||
| Operating cash flow | -$63.40M | -$55.56M | -$66.29M | -$58.79M | -$44.54M | -$54.53M | -$38.14M | -$48.47M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 | $0 | $35,000 | $176,000 |
| Free cash flow | -$63.40M | -$55.56M | -$66.29M | -$58.79M | -$44.54M | -$54.53M | -$38.17M | -$48.65M |
| Investing cash flow | -$58.76M | $322,000 | $98,000 | -$29.91M | $88.40M | $88.25M | $56.25M | -$147.33M |
| Financing cash flow | $26.97M | $234.62M | $30.64M | $72.39M | $480,000 | $0 | $73.12M | $151,000 |
| Depreciation & amortization | $905,000 | $896,000 | $845,000 | $751,000 | $745,000 | $742,000 | $378,000 | $364,000 |
| Stock-based compensation | $2.85M | $2.55M | $13.36M | $3.59M | $3.71M | $3.31M | $2.29M | $1.93M |
| Share buybacks | — | — | — | — | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.